HK1201155A1 - Basal insulin therapy - Google Patents

Basal insulin therapy Download PDF

Info

Publication number
HK1201155A1
HK1201155A1 HK15101611.0A HK15101611A HK1201155A1 HK 1201155 A1 HK1201155 A1 HK 1201155A1 HK 15101611 A HK15101611 A HK 15101611A HK 1201155 A1 HK1201155 A1 HK 1201155A1
Authority
HK
Hong Kong
Prior art keywords
patient
risk
reducing
basal insulin
insulin therapy
Prior art date
Application number
HK15101611.0A
Other languages
English (en)
Chinese (zh)
Inventor
Peter Johnston
Hertzel Gerstein
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of HK1201155A1 publication Critical patent/HK1201155A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15101611.0A 2012-03-28 2013-03-28 Basal insulin therapy HK1201155A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261616768P 2012-03-28 2012-03-28
US61/616,768 2012-03-28
US201261619641P 2012-04-03 2012-04-03
US61/619,641 2012-04-03
US201261624598P 2012-04-16 2012-04-16
US61/624,598 2012-04-16
US201261645909P 2012-05-11 2012-05-11
US61/645,909 2012-05-11
US201261701911P 2012-09-17 2012-09-17
US61/701,911 2012-09-17
PCT/EP2013/056661 WO2013144273A1 (en) 2012-03-28 2013-03-28 Basal insulin therapy

Publications (1)

Publication Number Publication Date
HK1201155A1 true HK1201155A1 (en) 2015-08-28

Family

ID=48044781

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101611.0A HK1201155A1 (en) 2012-03-28 2013-03-28 Basal insulin therapy

Country Status (13)

Country Link
US (1) US20150065421A1 (enExample)
EP (1) EP2830650A1 (enExample)
JP (1) JP2015512908A (enExample)
KR (1) KR20150001757A (enExample)
CN (1) CN104334183A (enExample)
AU (1) AU2013241776B2 (enExample)
CA (1) CA2865823A1 (enExample)
HK (1) HK1201155A1 (enExample)
IN (1) IN2014KN02335A (enExample)
MX (1) MX2014011687A (enExample)
RU (1) RU2014143271A (enExample)
SG (1) SG11201405433XA (enExample)
WO (1) WO2013144273A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017108943A1 (en) * 2015-12-23 2017-06-29 Sanofi-Aventis Deutschland Gmbh Cardiac metabolic effect of lantus
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
US20190357853A1 (en) * 2018-05-24 2019-11-28 Lizheng Shi Diabetes risk engine and methods thereof for predicting diabetes progression and mortality

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
PH12012502524A1 (en) * 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy

Also Published As

Publication number Publication date
KR20150001757A (ko) 2015-01-06
RU2014143271A (ru) 2016-05-20
SG11201405433XA (en) 2014-10-30
WO2013144273A1 (en) 2013-10-03
AU2013241776A1 (en) 2014-10-16
CN104334183A (zh) 2015-02-04
IN2014KN02335A (enExample) 2015-05-01
EP2830650A1 (en) 2015-02-04
US20150065421A1 (en) 2015-03-05
JP2015512908A (ja) 2015-04-30
MX2014011687A (es) 2015-05-11
AU2013241776B2 (en) 2017-11-02
CA2865823A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
MY167234A (en) Novel glucagon analogues
PH12012502524A1 (en) Diabetes therapy
MX2013011175A (es) Analogos de glucagon novedosos.
EP2605698A4 (en) Central site photoplethysmography, medication administration, and safety
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
PH12014501491A1 (en) Subcutaneous therapeutic use of dpp-4 inhibitor
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
MX363507B (es) Metodos para administrar óxido nítrico a la sangre arterial o arterializada.
MX2013013242A (es) Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal.
EP2682147A3 (en) System and method of controlling the delivery of medical gases to a patient
WO2014007972A3 (en) Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
PH12015501931B1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
WO2014153385A3 (en) Methods of treating metabolic disorders
WO2013087654A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
IN2014KN02335A (enExample)
WO2013083826A3 (en) Glp-1 agonists
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
UA104484C2 (uk) Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань
PH12014502497A1 (en) New treatments of hepatitis c virus infection
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
PL2852400T3 (pl) Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy
RU2011111051A (ru) Способ подавления эпилептиформной активности и купирования эпилептических приступов при эпилептических синдромах у детей с электрическим эпилептическим статусом в фазу медленного сна
UA79052U (ru) Способ иммунокоррекции при обострениях хронического бронхита у больных с инсулинорезистентностью
GB201217635D0 (en) Use of short term insulin treatment to restore pancreatic function in type 2 diabetic patients who have become refractory through oral hypolgycaemic agents